



Clinical trial results:

A Post Marketing Surveillance Study to monitor the reactogenicity and safety of Vaxem™Hib when administered according to the prescribing information in Korea.

Due to a system error, the data reported in v1 is not correct and has been removed from public view.

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2014-005203-24 |
| Trial protocol | Outside EU/EEA |
| Global end of trial date | 29 July 2012 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v2 (current) |
| This version publication date | 03 June 2016 |
| First version publication date | 21 March 2015 |
| Version creation reason | |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | V37_11 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01404962 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Novartis Vaccines and Diagnostics |
| Sponsor organisation address | Via Fiorentina 1, Siena, Italy, 53100 |
| Public contact | Posting Director, Novartis Vaccines and Diagnostics, RegistryContactVaccinesUS@novartis.com |
| Scientific contact | Posting Director, Novartis Vaccines and Diagnostics, RegistryContactVaccinesUS@novartis.com |

Notes:

Paediatric regulatory details

| | |
|--|-----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

Results analysis stage

| | |
|--|----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 19 August 2015 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 29 July 2012 |
| Global end of trial reached? | Yes |
| Global end of trial date | 29 July 2012 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To evaluate the safety and reactogenicity profile of VaxemHib in Korean children.

Protection of trial subjects:

Study vaccines were not administered to individuals with known hypersensitivity to any component of the vaccines. An oral temperature $\geq 38.0^{\circ}\text{C}$ ($\geq 100.4^{\circ}\text{F}$) or serious active infection was a reason for delaying vaccination. Standard immunization practices were observed and care was taken to administer the injection intramuscularly. As with all injectable vaccines, appropriate medical treatment and supervision was readily available in case of rare anaphylactic reactions following administration of the study vaccine. Epinephrine 1:1000 and diphenhydramine was available in case of any anaphylactic reactions. Care was taken to ensure that the vaccine is not injected into a blood vessel.

Background therapy:

N/A

Evidence for comparator:

N/A

| | |
|---|--------------|
| Actual start date of recruitment | 16 June 2011 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------------------|
| Country: Number of subjects enrolled | Korea, Republic of: 764 |
| Worldwide total number of subjects | 764 |
| EEA total number of subjects | 0 |

Notes:

Subjects enrolled per age group

| | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 761 |
| Children (2-11 years) | 3 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |

| | |
|---------------------|---|
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Subjects were enrolled from 23 centres in Korea.

Pre-assignment

Screening details:

All enrolled subjects were included in the trial.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|-----------|------------------|
| Arm title | VaxemHib Vaccine |
|-----------|------------------|

Arm description:

Subjects received 0.5 mL of VaxemHib vaccine as part of primary series or as a booster.

| | |
|--|--|
| Arm type | post marketing safety study |
| Investigational medicinal product name | Haemophilus influenza type b conjugate vaccine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection in pre-filled syringe |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose, pre-filled syringe containing 0.5 mL of liquid vaccine for intramuscular administration.

| | |
|---------------------------------------|------------------|
| Number of subjects in period 1 | VaxemHib Vaccine |
| Started | 764 |
| Completed | 743 |
| Not completed | 21 |
| Lost to follow-up | 21 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|------------------|
| Reporting group title | VaxemHib Vaccine |
|-----------------------|------------------|

Reporting group description:

Subjects received 0.5 mL of VaxemHib vaccine as part of primary series or as a booster.

| Reporting group values | VaxemHib Vaccine | Total | |
|------------------------|------------------|-------|--|
| Number of subjects | 764 | 764 | |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|---|---------|-----|--|
| Age continuous | | | |
| Subjects received 0.5mL of VaxemHib vaccine as part of primary series or as a booster | | | |
| Units: days | | | |
| arithmetic mean | 162.2 | | |
| standard deviation | ± 138.9 | - | |
| Gender categorical | | | |
| Subjects received 0.5mL of VaxemHib vaccine as part of primary series or as a booster | | | |
| Units: Subjects | | | |
| Female | 396 | 396 | |
| Male | 368 | 368 | |

End points

End points reporting groups

| | |
|--|-------------------------|
| Reporting group title | VaxemHib Vaccine |
| Reporting group description: | |
| Subjects received 0.5 mL of VaxemHib vaccine as part of primary series or as a booster. | |
| Subject analysis set title | All enrolled Population |
| Subject analysis set type | Safety analysis |
| Subject analysis set description: | |
| All subjects who have signed an informed consent and undergone procedure(s) for eligibility check for Post Marketing Surveillance | |
| Subject analysis set title | Safety Population |
| Subject analysis set type | Safety analysis |
| Subject analysis set description: | |
| All subjects who receive at least one vaccination and provide some safety data will be considered evaluable for the safety analyses. | |

Primary: Number of subjects who reported solicited local and systemic adverse events after vaccination with vaxemHib.

| | |
|--|---|
| End point title | Number of subjects who reported solicited local and systemic adverse events after vaccination with vaxemHib. ^[1] |
| End point description: | |
| Safety was assessed in terms of number of subjects who reported solicited local and systemic adverse events collected for 7 days after each vaccination. | |
| End point type | Primary |
| End point timeframe: | |
| Days 1 to 7 | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: statistical analyses not applicable for this endpoint.

| End point values | VaxemHib Vaccine | | | |
|---|------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 750 | | | |
| Units: Number of Subjects | | | | |
| Any Local | 90 | | | |
| Erythema (N = 741) | 8 | | | |
| Induration (N = 742) | 4 | | | |
| Tenderness (N = 742) | 80 | | | |
| Any Systemic | 222 | | | |
| Change in eating habits (N = 742) | 72 | | | |
| Persistent crying (N = 742) | 96 | | | |
| Irritability (N = 742) | 174 | | | |
| Vomiting (N = 742) | 46 | | | |
| Diarrhea (N = 742) | 36 | | | |
| Any Other | 36 | | | |
| Fever ($\geq 38^{\circ}\text{C}$)(N = 694) | 57 | | | |
| Temperature ($\geq 40^{\circ}\text{C}$) (N=694) | 1 | | | |
| Analgesic/Antipyretic medicines used (N = 750) | 36 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects reporting unsolicited AEs after vaccination with VaxemHib.

| | |
|-----------------|--|
| End point title | Number of subjects reporting unsolicited AEs after vaccination with VaxemHib. ^[2] |
|-----------------|--|

End point description:

Safety was assessed as the number of subjects who reported unsolicited AEs for 28 days after vaccination with VaxemHib.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Days 1 to 28

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: statistical analyses not applicable for this endpoint.

| End point values | VaxemHib Vaccine | | | |
|--|------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 750 | | | |
| Units: Number of Subjects | | | | |
| Any AE | 360 | | | |
| At least possibly or probably related AEs | 16 | | | |
| SAEs | 6 | | | |
| At least possibly or probably related SAEs | 0 | | | |
| AEs leading to withdrawal | 0 | | | |
| AEs leading to death | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Day 1 to day 28 after vaccination.

Adverse event reporting additional description:

For occurrences table MedDRA 17.1 version was used.

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 15.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|------------------|
| Reporting group title | VaxemHib Vaccine |
|-----------------------|------------------|

Reporting group description:

Subjects received 0.5 mL of VaxemHib vaccine as part of primary series or as a booster.

| Serious adverse events | VaxemHib Vaccine | | |
|--|------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 6 / 764 (0.79%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 764 (0.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 1 / 764 (0.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Bronchiolitis | | | |
| subjects affected / exposed | 1 / 764 (0.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumonia | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 764 (0.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 764 (0.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tonsillitis | | | |
| subjects affected / exposed | 1 / 764 (0.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 764 (0.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| | | | |
|---|---|--|--|
| Non-serious adverse events | VaxemHib Vaccine | | |
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 433 / 764 (56.68%) | | |
| General disorders and administration site conditions | | | |
| Crying | Additional description: For occurrences table MedDRA 17.1 version was used. | | |
| subjects affected / exposed | 125 / 764 (16.36%) | | |
| occurrences (all) | 145 | | |
| Injection Site Pain | Additional description: For occurrences table MedDRA 17.1 version was used. | | |
| subjects affected / exposed | 107 / 764 (14.01%) | | |
| occurrences (all) | 119 | | |
| Injection Site Erythema | Additional description: For occurrences table MedDra 17.1 version was used | | |
| subjects affected / exposed | 41 / 764 (5.37%) | | |
| occurrences (all) | 43 | | |
| Pyrexia | Additional description: For occurrences table MedDRA 17.1 version was used | | |
| subjects affected / exposed | 82 / 764 (10.73%) | | |
| occurrences (all) | 102 | | |

| | | | |
|---|-----------------------------|---|--|
| Gastrointestinal disorders | | | |
| | Diarrhoea | Additional description: For occurrences table MedDRA 17.1 version was used | |
| | subjects affected / exposed | 62 / 764 (8.12%) | |
| | occurrences (all) | 77 | |
| | Vomiting | Additional description: For occurrences table MedDRA 17.1 version was used | |
| | subjects affected / exposed | 56 / 764 (7.33%) | |
| | occurrences (all) | 72 | |
| | | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| | Cough | Additional description: For occurrences table MedDRA 17.1 version was used. | |
| | subjects affected / exposed | 117 / 764 (15.31%) | |
| | occurrences (all) | 133 | |
| | Rhinorrhoea | Additional description: For occurrences table MedDRA 17.1 version was used | |
| | subjects affected / exposed | 121 / 764 (15.84%) | |
| | occurrences (all) | 148 | |
| | | | |
| Psychiatric disorders | | | |
| | Eating Disorder | Additional description: For occurrences table MedDRA 17.1 version was used. | |
| | subjects affected / exposed | 86 / 764 (11.26%) | |
| | occurrences (all) | 99 | |
| | Irritability | Additional description: For occurrences table MedDRA 17.1 version was used. | |
| | subjects affected / exposed | 217 / 764 (28.40%) | |
| | occurrences (all) | 262 | |
| | | | |
| Infections and infestations | | | |
| | Bronchitis | Additional description: For occurrences table MedDra 17.1 version was used | |
| | subjects affected / exposed | 43 / 764 (5.63%) | |
| | occurrences (all) | 56 | |
| | Nasopharyngitis | Additional description: For occurrences table MedDRA 17.1 version was used. | |
| | subjects affected / exposed | 40 / 764 (5.24%) | |
| | occurrences (all) | 54 | |
| | | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported